What do we learn from HER2-positive breast cancer genomic profiles? - Archive ouverte HAL Access content directly
Journal Articles Breast Cancer Research Year : 2010

What do we learn from HER2-positive breast cancer genomic profiles?

(1)
1

Abstract

ABSTRACT: Patients with a tumor presenting amplification of the HER2 gene are currently proposed trastuzumab (herceptin) and this has greatly changed their outcome. However, a number of HER2-positive cancers show intrinsic or acquired resistance to trastuzumab and there are clear indications that they form a heterogeneous group of tumors. A paper in this issue of Breast Cancer Research addresses this heterogeneity at the genomic level.
Fichier principal
Vignette du fichier
bcr2571_Theillet_edited.pdf (147.68 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

inserm-00491423 , version 1 (11-06-2010)

Identifiers

Cite

Charles Theillet. What do we learn from HER2-positive breast cancer genomic profiles?. Breast Cancer Research, 2010, 12 (3), pp.107. ⟨10.1186/bcr2571⟩. ⟨inserm-00491423⟩
75 View
153 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More